Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer [Phase 1]
Phase 1 trial of 177Lu-PSMA-R2 in PSMA-positive metastatic castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating M6620 in combination with carboplatin, with or without docetaxel, for metastatic castration-resistant prostate canc…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial [Phase 2]
Phase 2 clinical trial investigating the combination of cabozantinib and atezolizumab for metastatic castration-resistant prostate cancer is…
-
CLINICAL_TRIALS research · 2025-05-04Clinical Trial Update: A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of copanlisib and rucaparib in metastatic castration-resistant prostate cancer; the…
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) [Phase 1]
A Phase 1 (Phase IB) trial evaluating Radium-223 dichloride in combination with niraparib for castration-resistant, metastatic prostate canc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy [Phase 2]
A Phase 2 clinical trial evaluating sacituzumab govitecan in metastatic castration-resistant prostate cancer that progressed on second-gener…
-
CLINICAL_TRIALS research · 2025-04-20Clinical Trial Update: Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating XNW5004 in combination with enzalutamide for metastatic castration-resistant prostate cancer is currentl…
-
CLINICAL_TRIALS trial_result · 2025-04-17Clinical Trial Update: A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer [Phase 2]
A Phase 2 trial comparing patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castration-resistant pro…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC [Phase 1]
Phase 1 study evaluating the combination of talazoparib and tazemetostat in metastatic castration-resistant prostate cancer, with the trial …
-
CLINICAL_TRIALS research · 2025-04-13Clinical Trial Update: Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of ebastine with docetaxel for metastatic castration-resistant prostate cancer; the…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC [Phase 1]
Phase 1 clinical trial evaluating the safety and preliminary efficacy of Universal PSMA CAR-T cells in patients with refractory metastatic c…
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer [Phase 3]
Phase 3 biomarker-driven trial (ProBio) in metastatic prostate cancer is currently recruiting, enrolling patients with metastatic castration…
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]
A Phase 1/2 trial of PLX2853 in combination with Abiraterone acetate and prednisone, and in combination with Olaparib, for Metastatic Castra…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the radioligand therapy [161Tb]Tb-PSMA-I&T in men with metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is investigating cabazitaxel in combination with 177Lu-PSMA-617 for metastatic castration-resistant prostate canc…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) [Phase 1]
JEWEL-101 is a Phase 1 trial of XB002 in patients with solid tumors, covering multiple indications. The study has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors [Phase 1, Phase 2]
Clinical trial update for TT-10 and TT-4 (Portage Biotech) exploring single-agent and combination therapy in advanced solid tumors, with rec…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 clinical evaluation of the radiopharmaceutical 177Lu-DansyI-PSMA (LNC1011) for metastatic castration-resistant prostate cancer has…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
A clinical trial evaluating whole-body MRI in metastatic castration-resistant prostate cancer patients treated with Lu-PSMA has been termina…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]
This clinical trial update reports that the Phase 1/2 study of ARV-110 in metastatic castration-resistant prostate cancer has been completed…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer [Phase 2]
A Phase 2 trial in men with advanced prostate cancer compares the combination of cediranib and olaparib to olaparib alone, with results post…
-
FDA approval · 2025-03-28FDA Approved: PLUVICTO — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for PLUVICTO (lutetium Lu-177 vipivotide tetraxetan) from Novartis Pharmaceuticals Corporation. The …
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer [Phase 2]
Phase 2 clinical trial to evaluate the efficacy and safety of different dose regimens of an oral cabazitaxel tablet in adults with metastati…
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer [Phase 1]
A Phase 1 clinical trial is evaluating 225Ac-PSMA-617 in men with PSMA-positive prostate cancer, including castration-resistant cases; the s…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications [Phase 1, Phase 2]
A Phase 1/2 clinical trial of KPT-8602 (eltanexor) in participants with relapsed/refractory cancer indications completed, evaluating safety,…